Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide

Radiotherapy and Oncology

Volumn 50, Issue 2, 1999, Pages 173-184

  Bussink, J ^a   Kaanders, J H A M ^a   Rijken, P F J W ^a   Peters, J P W ^a   Hodgkiss, R J ^b   Marres, H A M ^a   Van Der Kogel, A J ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Carbogen; Hypoxia; Nicotinamide; Perfusion; Proliferation; Vasculature

Indexed keywords

7 [4' (2 NITROIMIDAZOLE 1 YL)BUTYL]THEOPHYLLINE; BROXURIDINE; CARBOGEN; HOE 33342; NICOTINAMIDE; OXYGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOARCHITECTURE; DIFFUSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIMETRY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; VASCULARIZATION;

ANIMALS; ANOXIA; BENZIMIDAZOLES; BLOOD VESSELS; CARBON DIOXIDE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NIACINAMIDE; NITROIMIDAZOLES; OXYGEN; RADIATION-SENSITIZING AGENTS; THEOPHYLLINE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032944785     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00010-9     Document Type: Article

References (45)

1. Ang K.K., Trotti A., Garden A.S., et al. Overall time factor in postoperative radiation: results of a prospective randomized trial. Radiother Oncol. 40:1996;S30.
2. Bernsen H.J.J.A., Rijken P.F.J.W., Oostendorp T., Van der Kogel A.J. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br. J. Cancer. 71:1995;721-726.
3. Brown J.M., Giaccia A.J. Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol. 65:1994;95-102.
4. Bussink J., Kaanders J.H.A.M., Rijken P.F.J.W., Martindale C.A., Van der Kogel A.J. Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br. J. Cancer. 77:1998;57-64.
5. Chaplin D.J., Hill S.A., Bell K.M., Tozer G.M. Modification of tumour blood flow: current status and future directions. Semin. Rad. Oncol. 8:1998;151-163.
6. Cui Y., An S., Jabr S., Maturana J.A., Wu J.M., Gutstein W.H. The antiproliferative effects of nicotinamide and 3-aminobenzamide on human smooth muscle cells in vitro. Biochem. Mol. Biol. Int. 31:1993;935-944.
7. Dische S., Saunders M.I., Barrett A., Harvey A., Gibson D., Parmar M.K.B. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44:1997;123-136.
8. Dolbeare R., Gratzner H.G., Palavicini M.G., Gray J.W. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. USA. 80:1983;5573-5577.
9. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;831-838.
10. Gratzner H.G. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine a new reagent for detection of DNA replication. Science. 218:1982;474-475.
11. Hiromatsu Y., Sato M., Yamada K., Nonaka K. Inhibitory effects of nicotinamide on recombinant human interferon-γ induced intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial cells. Immunol. Lett. 31:1991;35-40.
12. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:1993;45-50.
13. Hodgkiss R.J., Jones G., Long A., et al. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer. 63:1991;119-125.
14. Hodgkiss R.J., Wardman P. The measurement of hypoxia in tumours. Br. J. Radiol. ; Suppl. 24:1992;105-110.
15. Honess D.J., Bleehen N.M. Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br. J. Cancer. 71:1995;1175-1180.
16. Horiot J.C., Bontemps P., Van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol. 44:1997;111-121.
17. Horsman M.R., Chaplin D.J., Brown J.M. Tumor radiosensitization by nicotinamide: a result of improved blood perfusion and oxygenation. Radiat. Res. 118:1989;139-150.
18. Horsman M.R., Overgaard J. Overcoming tumor radiation resistance resulting from acute hypoxia. Eur. J. Cancer. 28:1992;717-718.
19. Horsman M.R., Nordsmark M., Khalil A.A., et al. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol. 33:1994;371-376.
20. Hoshino T., Nagashima T., Murovic J., Levin E.M., Levin V.A., Rupp S.M. Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. Cytometry. 6:1985;627-632.
21. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., Van der Maazen R.W.M., Van der Kogel A.J., Van Daal W.A.J. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Radiother. Oncol. 37:1995;190-198.
22. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., Liefers J., Van den Hoogen F.J.A., Van Daal W.A.J., Van der Kogel A.J. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol. 48:1998;115-122.
23. Kennedy A.S., Raleigh J.A., Perez G.M., Calkins D.P., Thrall D.E., Novotny D.B., Varia M.A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays. Int. J. Rad. Oncol. Biol. Phys. 37:1997;897-905.
24. Kjellen E., Joiner M.C., Collier J.M., Johns H., Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22:1991;81-91.
25. Long A., Parrick J., Hodgkiss R.J. An efficient procedure for the 1-alkylation of 2-nitroimidazoles and the synthesis of a probe for hypoxia in solid tumours. Synthesis. 9:1991;709-713.
26. Martin L., Lartigau E., Weeger P., et al. Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother. Oncol. 27:1993;123-130.
27. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-39.
28. Olive P.L., Vikse C., Trotter M.J. Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;397-402.
29. Olive P.L. Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother. Oncol. 32:1994;37-46.
30. Overgaard J., Sand Hansen H., Overgaard M., et al. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week. Report from the DAHANCA 7 trial. Int. J. Rad. Oncol. Biol. Phys. 39:1997;S188.
31. Pötgens A.J.G., Lubsen N.H., Van Altena M.C., Schoenmakers J.C.G., Ruiter D.J., De Waal R.M.W. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am. J. Pathol. 146:1995;197-209.
32. Powell M.E.B., Hill S.A., Saunders M.I., Hoskin P.J., Chaplin D.J. Effect of carbogen breathing on tumour microregional blood flow in humans. Radiother. Oncol. 41:1996;225-231.
33. Raleigh J.A., Miller G.G., Franko A.J., Koch C.J., Fuciarelli A.F., Kelly D.A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer. 56:1987;395-400.
34. Rijken P.F.J.W., Bernsen H.J.J.A., Van der Kogel A.J. Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc. Res. 50:1995;141-153.
35. Rojas A., Joiner M.C., Denekamp J. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy. Radiother. Oncol. 24:1992;123-124.
36. Stratford M.R.L., Dennis M.F. Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. Cancer Chemother. Pharmacol. 34:1994;399-404.
37. Trotter M.J., Olive P.L., Chaplin D.J. Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br. J. Cancer. 62:1990;903-908.
38. Van der Sanden B.P.J., Heerschap A., Hoofd L., et al. Effect of carbogen breathing on the physiological profile of human glioma xenografts. Magnet. Res. Med. 1999;. in press.
39. Walenta S., Mueller-Klieser W. Oxygen consumption rate of tumour cells as a function of their proliferative status. Adv. Exp. Med. Biol. 215:1987;389-391.
40. Webster L., Hodgkiss R.J., Wilson G.D. Simultaneous triple staining for hypoxia, proliferation, and DNA content in murine tumours. Cytometry. 21:1995;344-351.
41. Webster L., Hodgkiss R.J., Wilson G.D. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br. J Cancer. 77:1998;227-234.
42. Westphal J.R., Van't Hullenaar R.G.M., Van der Laak J.A.W.M., et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br. J. Cancer. 76:1997;561-570.
43. Withers H.R., Taylor J.M.G., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.
44. Young W.K., Vojnovic B., Wardman P. Measurement of oxygen tension in tumours by time-resolved fluorescence. Br. J. Cancer. 74:(Suppl. XXVII):1996;S256-S259.
45. Zhu M., Noma Y., Mizuno A., Sano T., Shima K. Poor capacity for proliferation of pancreatic b-cells in Otsuka-Long Evans-Tokushima Fatty rat: a model of spontaneous NIDDM. Diabetes. 45:1996;941-946.